N-Terminal Truncated Intracellular Matrix Metalloproteinase-2 Induces Cardiomyocyte Hypertrophy, Inflammation and Systolic Heart Failure

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Lovett, David H ^a   Mahimkar, Rajeev ^a,b   Raffai, Robert L ^a   Cape, Leslie ^a   Zhu, Bo Qing ^a   Jin, Zhu Qiu ^a,c   Baker, Anthony J ^a   Karliner, Joel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

^c SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; ISOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTOME;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; ENZYME ACTIVATION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HUMAN; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; INTRON; MITOCHONDRION; MONONUCLEAR CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; REPERFUSION INJURY; SYSTOLIC HEART FAILURE;

ANIMALS; HEART FAILURE, SYSTOLIC; INFLAMMATION; INTERFERON REGULATORY FACTOR-7; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 2; MICE; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PROTEIN ISOFORMS;

EID: 84880490119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068154     Document Type: Article

References (42)

1. Lovett DH, Mahimkar R, Raffai RL, Cape L, Maklashina E, et al. (2012) A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 7: e34177-e34191.
2. Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, et al. (1999) Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284: 1667-70.
3. Zhang S, Picard MH, Vasile E, Zhu Y, Raffai RL, et al. (2005) Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction and premature death in scavenger receptor Class B Type-deficient hypomorphic Apolipoprotein ER61 mice. Circulation 111: 3457-3464.
4. Bergman M, Teerlink JR, Mahimkar R, Li L, Zhu B-Q, et al. (2007) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292: H1847-1860.
5. Fleischmann M, Block W, Kolossov E, Andressen C, Muller M, et al. (1998) Cardiac specific expression of the green fluorescent protein during early murine embryonic development. FEBS Lett 440: 370-376.
6. Xian M, Honbo N, Zhang J, Liew C-C, Karliner JS, et al. (1999) The green fluorescent protein is an efficient biologic marker for cardiac myocytes. J Mol Cell Cardiol 31: 2155-2165.
7. Caron KM, Smithies O, (2001) Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci USA 98: 615-619.
8. Rex TS, Peet JA, Surace EM, Calvert PD, Nikonov SS, et al. (2005) The distribution, concentration and toxicity of enhanced green fluorescent protein in retinal cells after genomic or somatic (virus-mediated) gene transfer. Mol Vision 11: 1236-1245.
9. Liu Y, Wu Q, Cui H, Li Q, Zhao Y, et al. (2008) Expression of EGFP and NPTII protein is not associated with organ abnormalities in deceased transgenic cloned cattle. Cloning and Stem Cells 10: 421-428.
10. Bergmann U, Tuuttila A, Stetler-Stevenson WG, Tryggvason K, (1995) Autolytic activation of recombinant human 72 kDa Type IV collagenase. Biochem 34: 2819-2825.
11. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G, (1996) The soluble catalytic domain of membrane Type I matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. J Biol Chem 271: 1719-1723.
12. Abbate A, De Falco M, Morales C, Gellpi RJ, Prisco M, et al. (2007) Electron microscopy characterization of cardiomyocyte apoptosis in ischemic heart disease. Int J Cardiol 114: 118-120.
13. Arbustini E, Brega A, Narula J, (2008) Ultrastructural definition of apoptosis in heart failure. Heart Fail Rev 13: 121-135.
14. Wang G-Y, Bergman MR, Nguyen AP, Turcato S, Swigart PM, et al. (2006) Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69: 688-696.
15. Arnold G, Kaiser C, Fischer R, (1985) Myofibrillar degeneration-a common type of myocardial lesion and its selective identification by a modified Luxol Fast Blue stain. Pathol Res Pract 180: 405-415.
16. Li J, Leschka S, Rutschow S, Schimmbeck PL, Husmann L, et al. (2007) Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol 554: 60-68.
17. Spinale FG, (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87: 1285-1342.
18. Hayashidani S, Tsutsui T, Ikeuchi M, Siomi T, Matsusaka H, et al. (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285: H1229-H1235.
19. Yamazaki T, Lee JD, Shimizu H, Uzui H, Ueda T, (2004) Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 6: 41-45.
20. Shirakabe A, Asai K, Hata N, Yokoyama S, Shinada T, et al. (2010) Clinical significance of matrix metalloproteinase-2 in patients with acute heart failure. Int Heart J 51: 404-410.
21. Mahimkar R, Nguyen A, Mann M, Yeh CC, Zhu B-Q, et al. (2009) Cardiac transgenic matrix metalloprpoteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapsed disease. Cardiovasc Pathol 18: 253-261.
22. Dahi S, Karliner JS, Sarkar R, Lovett DH, (2011) Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. Int J Exp Pathol. 92: 50-56.
23. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, et al. (2002) Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549.
24. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, et al. (2005) Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112: 544-552.
25. Schulz R, (2009) Intracellular targets of matrix metalloproteinase-2 in cardiac disease. Ann Rev Pharmacol Toxicol 47: 211-242.
26. Ali MA, Chow AK, Dandasamy AD, Fan X, West LG, et al. (2012) Mechanisms of cystosolic targeting of matrix metalloproteinase-2. J Cell Physiol 227: 3397-33404.
27. Molkentin JD, Lu RJ, Anto CL, Markham B, Richardson J, et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228.
28. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, et al. (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94: 110-118.
29. Heineke J, Molkentin JD, (2006) Regulation of cardiac hypertrophy by intracellular signaling pathways. Nat Rev Mol Cell Biol 7: 589-600.
30. Liu Q, Chen Y, Auger-Messier N, Molkentin JD, (2012) Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110: 1077-1086.
31. Gordon JW, Shaw JA, Kirschenbaum LA, (2011) Multiple facets of NF-κB in the heart. To be or not to NF-κB. Circ Res 108: 1122-1132.
32. Supta S, Young D, Maitra RK, Gupta A, Popovic ZB, et al. (2008) Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 375: 637-649.
33. Mann DL, (2011) The emerging role of the innate immunity in the heart and vascular system. For whom the cell tolls. Circ Res 108: 1133-1145.
34. Arslan F, de Kleign DP, Pasterkamp G, (2011) Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 8: 292-300.
35. Valen G, (2011) Innate immunity and remodeling. Heart Failr Rev 16: 71-78.
36. Zhou H-Z, Ma X, Gray MO, Zhu B-Q, Nguyen AP, et al. (2007) Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochim Biophys Res Comm 358: 189-195.
37. Hori Y, Kashimoto T, Yonezawa T, Sano N, Saitoh R, et al. (2012) Matrix metalloproteinase-2 stimulates collagen-1 expression through phosphorylation of focal adhesion kinase in rat cardiac fibroblasts. Am J Physiol Cell Physiol, ePub in press.
38. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, et al. (2003) A functional AP-2 site regulates cardiac cell-specific MMP-2 transcription through interactions with JunB/Fra1 and JunB/FosB heterodimers. Biochem J 369: 485-496.
39. Alfonso-Jaume MA, Bergman MR, Mahimmkar R, Cheng S, Jin ZQ, et al. (2006) Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 291: H1838-H1846.
40. McMillan JI, Riordan JW, Couse WG, Pollock AS, Lovett DH, (1996) Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest 97: 1094-1101.
41. Castro MM, Tanus-Santos JE, (2013) Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to amerliorate hypertension-induced cardiovascular alterations. Curr Drug Targets 14: 335-343.
42. Rizzi E, Castro MM, Ceron CS, Neto-Neves EM, Prado CM, et al. (2013) Tempol inhibits TGF-β and MMMPs upregulation and prevents cardiac hypertensive changes. Inter J Cardiol 165: 165-173.